Axonics Inc AXNX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AXNX is a good fit for your portfolio.
News
-
Boston Scientific Announces Results for First Quarter 2024
-
Axonics Stockholders Approve Merger Agreement with Boston Scientific
-
Axonics Provides Update on Inter Partes Review Proceedings
-
Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
-
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates MDC, AXNX, CPE
-
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger – KAMN, JNPR, INBX, AXNX
-
Axonics Responds to ITC Action by Medtronic
-
Axonics Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Trading Information
- Previous Close Price
- $66.64
- Day Range
- $66.46–66.77
- 52-Week Range
- $47.59–69.68
- Bid/Ask
- $66.49 / $67.50
- Market Cap
- $3.39 Bil
- Volume/Avg
- 484,280 / 890,603
Key Statistics
- Price/Earnings (Normalized)
- 81.84
- Price/Sales
- 8.93
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is predominantly used to treat patients with overactive bladder, fecal incontinence, and urinary retention. Geographically, the company generates majority of its revenue from United States and rest from International markets.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 797
- Website
- https://www.axonics.com
Comparables
Valuation
|
Metric
|
AXNX
|
NARI
|
ATEC
|
|---|---|---|---|
Price/Earnings (Normalized) | 81.84 | 410.19 | — |
Price/Book Value | 5.31 | 4.74 | 22.71 |
Price/Sales | 8.93 | 4.39 | 3.20 |
Price/Cash Flow | 89.07 | 65.11 | — |
Price/Earnings
AXNX
NARI
ATEC
Financial Strength
|
Metric
|
AXNX
|
NARI
|
ATEC
|
|---|---|---|---|
Quick Ratio | 8.78 | 2.43 | 1.86 |
Current Ratio | 10.73 | 3.09 | 2.86 |
Interest Coverage | — | −56.99 | −10.23 |
Quick Ratio
AXNX
NARI
ATEC
Profitability
|
Metric
|
AXNX
|
NARI
|
ATEC
|
|---|---|---|---|
Return on Assets (Normalized) | 5.93% | 5.07% | −9.89% |
Return on Equity (Normalized) | 6.64% | 6.37% | — |
Return on Invested Capital (Normalized) | 4.55% | 3.35% | −9.94% |
Return on Assets
AXNX
NARI
ATEC
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Vznnvvs | Gwvsr | $185.5 Bil | |
SYK
| Stryker Corp | Cmqlzcvb | Xyhlq | $128.2 Bil | |
MDT
| Medtronic PLC | Zwvzzvwzs | Xrthspj | $106.7 Bil | |
BSX
| Boston Scientific Corp | Nkywgzcv | Wqvlcj | $99.0 Bil | |
DXCM
| DexCom Inc | Fhtvhppzgt | Flh | $53.1 Bil | |
EW
| Edwards Lifesciences Corp | Zrbbgjth | Hyyyfw | $52.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Pvrxgwww | Bqhrp | $24.9 Bil | |
ALGN
| Align Technology Inc | Fhxszmv | Wxfqqvd | $23.5 Bil | |
PHG
| Koninklijke Philips NV ADR | Bqbdckl | Pfzsxg | $18.9 Bil | |
PODD
| Insulet Corp | Vkxtjscln | Fsrvrn | $11.7 Bil |